诺氟沙星一级预防用于APASL定义的慢加急性肝衰竭:安慰剂对照双盲随机试验
本研究纳入143例APASL定义的慢加急性肝衰竭患者,随机分为诺氟沙星组(72例)和安慰剂组(71例),口服诺氟沙星400 mg或安慰剂每日一次共30天。诺氟沙星组第30天和第90天细菌感染发生率均低于安慰剂组,但无移植生存率两组无显著差异。
要点
- 诺氟沙星组第30天细菌感染发生率18.1% vs 安慰剂组33.8%(P=0.03)。
- 诺氟沙星组第90天细菌感染发生率46% vs 安慰剂组62%(P=0.02)。
- 第30天和第90天无移植生存率两组无显著差异(P=0.084和P=0.058)。
核心结论
- 诺氟沙星一级预防可有效预防APASL定义的慢加急性肝衰竭患者的细菌感染。
研究设计与样本
- 安慰剂对照双盲随机试验,纳入143例APASL定义的慢加急性肝衰竭患者,诺氟沙星组72例,安慰剂组71例。
主要发现
- 诺氟沙星组第30天细菌感染发生率为18.1%(95%CI 10-28.9),安慰剂组为33.8%(95%CI 23-46),P=0.03。
- 诺氟沙星组第90天细菌感染发生率为46%(95%CI 34-58),安慰剂组为62%(95%CI 49.67-73.23),P=0.02。
- 诺氟沙星组第30天无移植生存率为77.8%(95%CI 66.43-86.73),安慰剂组为64.8%(95%CI 52.54-75.75),P=0.084。
- 诺氟沙星组第90天无移植生存率为58.3%(95%CI 46.11-69.84),安慰剂组为43.7%(95%CI 31.91-55.95),P=0.058。
- 30%的感染由多重耐药菌引起;诺氟沙星组25%患者出现伴发念珠菌尿,安慰剂组为2.63%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This study aimed to evaluate the role of prophylactic norfloxacin in preventing bacterial infections and its effect on transplant-free survival (TFS) in patients with acute-on-chronic liver failure (ACLF) identified by the Asian Pacific Association for the Study of the Liver criteria. METHODS: Patients with ACLF included in the study were randomly assigned to receive oral norfloxacin 400 mg or matched placebo once daily for 30 days. The incidence of bacterial infections at days 30 and 90 was the primary outcome, whereas TFS at days 30 and 90 was the secondary outcome. RESULTS: A total of 143 patients were included (72 in the norfloxacin and 71 in the placebo groups). Baseline demographics, biochemical variables, and severity scores were similar between the 2 groups. On Kaplan-Meier analysis, the incidence of bacterial infections at day 30 was 18.1% (95% confidence interval [CI], 10-28.9) and 33.8% (95% CI, 23-46) (P = 0.03); and the incidence of bacterial infections at day 90 was 46% (95% CI, 34-58) and 62% (95% CI, 49.67-73.23) in the norfloxacin and placebo groups, respectively (P = 0.02). On Kaplan-Meier analysis, TFS at day 30 was 77.8% (95% CI, 66.43-86.73) and 64.8% (95% CI, 52.54-75.75) in the norfloxacin and placebo groups, respectively (P = 0.084). Similarly, TFS at day 90 was 58.3% (95% CI, 46.11-69.84) and 43.7% (95% CI, 31.91-55.95), respectively (P = 0.058). Thirty percent of infections were caused by multidrug-resistant organisms. More patients developed concomitant candiduria in the norfloxacin group (25%) than in the placebo group (2.63%). DISCUSSION: Primary norfloxacin prophylaxis effectively prevents bacterial infections in patients with ACLF.
引用
- Kulkarni AV, Tirumalle S, Premkumar M, et al. Primary Norfloxacin Prophylaxis for APASL-Defined Acute-on-Chronic Liver Failure: A Placebo-Controlled Double-Blind Randomized Trial. Am J Gastroenterol. 2022. PMID: 35041634. doi:10.14309/ajg.0000000000001611
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。